We are live on ! Find out more
Prosight Management

Prosight Management Portfolio holdings

AUM $515M Turnover 48.89%
1-Year Est. Return 2.95%
This Fund
S&P 500
This Quarter Est. Return
-0.46%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$23.5M
Cap. Flow
+$19.6M
Cap. Flow %
12.32%
Top 10 Hldgs %
62.97%
Holding
41
New
12
Increased
6
Reduced
13
Closed
10
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Top Buys

Rank Stock Value
1
SHPG
Shire
SHPG
+$20.1M
2
TLGT
Teligent
TLGT
+$7.87M
3
SRRA
Sierra Oncology
SRRA
+$7.2M
4
CI icon
Cigna
CI
+$6.26M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.44M

Top Sells

Rank Stock Value
1
CMRX icon
Chimerix
CMRX
+$6.85M
2
QURE icon
uniQure
QURE
+$5.47M
3
CNC icon
Centene
CNC
+$4.97M
4
RXDX
Ignyta
RXDX
+$4.58M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.5M

Sector Composition

Rank Sector Weight
1 Healthcare 85.12%
2 Real Estate 6.42%
3 Consumer Discretionary 4.74%
4 Miscellaneous 3.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
SHPG
1
DELISTED
Shire
SHPG
$21.8M 13.69%
+146,114
New +$20.1M
2018 Q1
0 quarters
AGN
2
DELISTED
Allergan plc
AGN
$16M 10.01%
94,800
-3,200
-3% -$537K
2017 Q4
1 quarter
MGNX icon
3
MacroGenics
MGNX
$127M
$11.2M 7.02%
445,000
-162,696
-27% -$3.95M
2017 Q4
1 quarter
SBRA icon
4
Sabra Healthcare REIT
SBRA
$5.36B
$10.2M 6.42%
580,000
+177,943
+44% +$3.14M
2017 Q4
1 quarter
AKAO
5
DELISTED
Achaogen Inc
AKAO
$8.56M 5.37%
661,054
+90,134
+16% +$1.02M
2017 Q4
1 quarter
TLGT
6
DELISTED
Teligent
TLGT
$8.31M 5.21%
+247,256
New +$7.87M
2018 Q1
0 quarters
AFAM
7
DELISTED
Almost Family Inc
AFAM
$7.56M 4.74%
135,000
+44,452
+49% +$2.56M
2017 Q4
1 quarter
RETA
8
DELISTED
Reata Pharmaceuticals
RETA
$6.11M 3.83%
297,750
+124,853
+72% +$3.21M
2017 Q4
1 quarter
CI icon
9
Cigna
CI
$71.9B
$5.4M 3.39%
+32,200
New +$6.26M
2018 Q1
0 quarters
SRRA
10
DELISTED
Sierra Oncology
SRRA
$5.26M 3.3%
+63,463
New +$7.2M
2018 Q1
0 quarters
EIGR
11
DELISTED
Eiger BioPharmaceuticals
EIGR
$5.23M 3.28%
17,695
-4,931
-22% -$1.46M
2017 Q4
1 quarter
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$11.9B
$5.14M 3.22%
+63,400
New +$5.44M
2018 Q1
0 quarters
DXCM icon
13
DexCom
DXCM
$29.9B
$4.82M 3.02%
260,000
+135,208
+108% +$2M
2017 Q4
1 quarter
ARNA
14
DELISTED
Arena Pharmaceuticals
ARNA
$4.76M 2.98%
+120,400
New +$4.68M
2018 Q1
0 quarters
CDTX icon
15
DELISTED
Cidara Therapeutics
CDTX
$4.75M 2.98%
59,318
-23,076
-28% -$3.15M
2017 Q4
1 quarter
PVLA icon
16
Palvella Therapeutics
PVLA
$2.13B
$3.84M 2.41%
+7,047
New +$4.36M
2018 Q1
0 quarters
IOVA icon
17
Iovance Biotherapeutics
IOVA
$3.38B
$3.55M 2.22%
209,842
-297,010
-59% -$4.5M
2017 Q4
1 quarter
INGN icon
18
PUT
Inogen
INGN
$141M
$3.29M 2.06%
+26,800
New +$3.27M
2018 Q1
0 quarters
QTNT
19
DELISTED
Quotient Ltd
QTNT
$3.21M 2.02%
17,055
-6,258
-27% -$1.13M
2017 Q4
1 quarter
AVEO
20
DELISTED
AVEO Pharmaceuticals
AVEO
$3.03M 1.9%
104,355
-1,414
-1% -$41.4K
2017 Q4
1 quarter
CLVS
21
CALL
DELISTED
Clovis Oncology
CLVS
$2.64M 1.66%
+50,000
New +$2.92M
2018 Q1
0 quarters
CIVI icon
22
DELISTED
Civitas Solutions
CIVI
$2.53M 1.59%
+164,396
New +$2.5M
2018 Q1
0 quarters
CNC icon
23
Centene
CNC
$32.5B
$2.5M 1.57%
46,750
-95,250
-67% -$4.97M
2017 Q4
1 quarter
CLVS
24
DELISTED
Clovis Oncology
CLVS
$2.43M 1.52%
46,001
+6,001
+15% +$350K
2017 Q4
1 quarter
PRTK
25
DELISTED
Paratek Pharmaceuticals
PRTK
$1.93M 1.21%
148,682
-29,771
-17% -$443K
2017 Q4
1 quarter

Similar funds

Prosight Management's Q1 2018 Portfolio in Review

As of Q1 2018, Prosight Management held 41 positions worth $159M, up 17% from $136M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Prosight Management deployed $19.6M of net new capital in Q1 2018, opening 12 new positions and adding to 6 existing holdings. Its largest new stake was Shire: 146,114 shares worth $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 90% a quarter earlier, followed by Real Estate and Consumer Discretionary.

On the sell side, the largest reduction was uniQure, an estimated $5.47M trimmed.

  • Prosight Management's largest Q1 2018 buy was Shire: 146,114 shares worth $21.8M.
  • Prosight Management added most to Reata Pharmaceuticals in Q1 2018, an estimated $3.21M increase.
  • Prosight Management's biggest Q1 2018 reduction was uniQure, cutting an estimated $5.47M.
  • Prosight Management fully exited Chimerix in Q1 2018, selling an estimated $6.85M.
  • Prosight Management's ten largest holdings make up 63% of its $159M portfolio in Q1 2018.
  • Prosight Management opened 12 new positions and closed 10 in Q1 2018.
  • Prosight Management's portfolio value rose 17% quarter-over-quarter to $159M.

Based on Prosight Management's 13F filing for Q1 2018, filed 14 May 2018.